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Abstract 
 
Aim: Both the ankle brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) 
are surrogates for atherosclerosis. The present study aimed to evaluate the ability of the ABI 
and baPWV to predict stroke outcome in first-ever non-cardioembolic stroke patients. 
Methods: This study included consecutive patients with first-ever non-cardioembolic stroke 
who were admitted within 1 week after onset to Ota Memorial Hospital between January 2011 
and December 2013. Baseline characteristics and NIHSS scores at admission were noted. The 
ABI and baPWV were evaluated within 5 days after admission. The patients were categorized 
according to the ABI (cutoff 0.9) and baPWV cutoff 1870 cm/s determined with receiver 
operation curve for poor outcome. Clinical outcomes were defined based on the modified 
Rankin Scale (mRS) scores 3 months after stroke onset as good (0 and 1) or poor (2–6). 
Results: A total of 861 patients were available for evaluation. An ABI <0.9 and a baPWV 
>1870 cm/s were associated with poor outcome in the univariate analysis (p < 0.001 and p < 
0.001, respectively). After adjusting for factors that showed differences between groups, an 
ABI <0.9 was associated with poor outcome. Among patients with an ABI ≥0.9, a higher 
baPWV showed a slight association with poor outcome after adjustment (odds ratio 1.46 
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[95%CI 0.95–2.27]). 
Conclusion: Our study suggests that the stroke outcome can be predicted with the ABI, and 
slightly with baPWV when ABI ≥0.9 in non-cardioembolic stroke patients. 
 
Key words: ankle brachial index, brachial-ankle pulse wave velocity, ischemic stroke, 
non-cardioembolic stroke, outcome, modified Rankin Scale 
 
Running title: ABI and baPWV can predict stroke outcome 
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Introduction 
 Atherothrombosis has been proposed as a composite disease that includes myocardial 
infarction, non-cardioembolic stroke, and peripheral artery disease. This is reasonable because 
each of the conditions is based on systemic atherosclerosis. Additionally, peripheral artery 
disease can be highly complicated with stroke. In the REACH Registry, 8.5% of prior stroke 
and transient ischemic attack patients had peripheral artery disease, and 23.0% of peripheral 
artery disease patients had stroke and transient ischemic attack1). Additionally, 2.6% of 
peripheral artery disease patients developed nonfatal stroke and 8.8% died from stroke or 
myocardial infarction during a 2-year follow-up period2). 
 Pulse wave velocity (PWV) reflects segmental arterial elasticity. Although 
carotid-femoral PWV is currently the gold standard measurement method, brachial-ankle 
PWV (baPWV) is more convenient method and widely available. It is well correlated with 
carotid-femoral PWV and reflects central arterial stiffness3, 4). BaPWV is associated with 
subclinical stage of atherosclerosis and is an independent predictor of future cardiovascular 
events 5, 6). Recently, the ankle brachial index (ABI) and baPWV were reported as predictive 
factors of stroke outcome7-10). Additionally, there is an inter-influence between atherosis and 
sclerosis, with ABI reflecting arterial atherosis11) and baPWV reflecting sclerosis12, 13). 
However, it has been reported that the accuracy of baPWV for the evaluation of 
pathophysiological conditions related to atherosclerosis diminishes when the ABI is low14, 15). 
Therefore, with regard to atherosclerosis pathophysiology, the ABI and baPWV are related. 
Previous studies have not considered the relation of the ABI and baPWV in the evaluation of 
their influence on stroke outcomes. 
 
Aim 
 The present study aimed to evaluate the ability of the ABI and baPWV to predict 
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stroke outcome in first-ever non-cardioembolic stroke patients. We hypothesized that the ABI 
and baPWV may be effect modifier of each other with their influence on stroke outcome. 
Additionally, the influence of the baPWV on stroke outcome may differ between patients with 
an ABI <0.9 and those with an ABI ≥0.9. 
 
Methods 
Study design and participants 
 A total of 2413 patients with acute ischemic stroke, without transient ischemic attack, 
who were admitted to our Brain Attack Center between January 2011 and December 2013, 
were considered for inclusion in this study. Among these patients, 597 cardioembolic stroke 
patients, 730 patients with a prior stroke history, 76 patients who were admitted later than 7 
days after stroke onset, 92 patients with tissue plasminogen activator treatment, 142 patients 
who received endovascular therapy, 62 patients who underwent surgical operation, and 546 
patients with premorbid mRS ≥2 were excluded from this study. In addition, there were 105 
patients without available ABI and baPWV data, and 53 patients without 3-month modified 
Rankin Scale (mRS) data. Finally, 861 first-ever acute non-cardioembolic stroke patients (285 
female patients; mean age, 70.2 ± 11.6 years) were available for evaluation in this study 
(Figure 1). This study was approved by the institutional review board of Brain Attack Center 
Ota Memorial Hospital (No. 133) and was performed according to the Ethical Guidelines for 
Medical and Health Research Involving Human Subject16) based on the Helsinki Declaration 
of 1964. This was a retrospective study, thus we did not obtain the patient’s consent. 
Diagnosis of stroke and date collection 
 The final diagnosis of the stroke subtype was made before discharge using 
echocardiography, brain computed tomography, magnetic resonance imaging, magnetic 
resonance angiography, or carotid ultrasonography, according to the Trial of Org 10172 in 
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Acute Stroke Treatment classification17). Physicians collected detailed data from all patients, 
including baseline characteristics (age, sex, body mass index (BMI), and drinking and 
smoking habits), vascular risk factors (hypertension, dyslipidemia, and diabetes mellitus), 
usage of antithrombotic agent prior to the stroke incidence, and neurologic deficits at 
admission using the National Institutes of Health stroke scale (NIHSS) score. Hypertension 
was defined as the use of anti-hypertensive medications prior to admission or a confirmed 
blood pressure ≥140/90 mmHg 2 weeks after stroke onset. Diabetes mellitus was defined as 
an HbA1c value of ≥6.5%, a fasting blood sugar level ≥126 mg/dL, or the use of anti-diabetic 
medications. Dyslipidemia was defined as a total cholesterol level ≥220 mg/dL, low-density 
lipoprotein cholesterol level ≥140 mg/dL, high-density lipoprotein cholesterol level <40 
mg/dL, triglyceride level ≥150 mg/dL at admission, or the use of anti-dyslipidemia 
medications. The mRS scores were evaluated 3 months after onset, and the patients were 
categorized into good outcome (mRS score, 0 and 1) or poor outcome (mRS score, 2–6). 
Measurements of ABI and baPWV 
 The ABI and baPWV were evaluated within 5 days after hospitalization. 
Brachial-ankle arterial blood pressures were simultaneously measured using a noninvasive 
automatic device (model BP-203RPE-III; Nihon Colin, Tokyo, Japan) after a 5-minute rest in 
the supine position. The ABI was defined as the ratio of systolic blood pressure in the ankle 
(dorsalis pedis and posterior tibial arteries) and the higher side of the 2 brachial arteries. The 
laterality, which showed a lower ABI, was used for evaluation. The baPWV on each side was 
calculated as the transmission distance divided by the transmission time. The transmission 
time between the right arm and both ankles was calculated using the waveform. The 
transmission distance between the right brachium and ankle was automatically calculated 
according to the height of the patient. The baPWV was evaluated on the higher side. 
Statistical analysis 
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 The data are expressed as mean ± standard deviation (SD) or median (25th and 75th 
percentiles) for continuous variables and as frequency and percentage for discrete variables. 
The statistical significance of intergroup differences was assessed by using the analysis of 
variance, Kruskal-Wallis test, or χ2 test, as appropriate. Univariate and multivariate logistic 
regression analyses were performed to evaluate the association of factors with poor outcome, 
and the odds ratios and 95% confidence intervals were calculated. Receiver operation 
characteristic curve was used to determine a cutoff baPWV for predicting poor outcome. In 
multivariate logistic regression analysis, factors that showed intergroup difference on 
evaluation with p-values <0.2 in the univariate analysis were used for adjustment. Statistical 
significance was set at a p-value <0.05. All statistical analyses were performed using JMP 
12.0.1 statistical software (SAS Institute Inc., Cary, NC, USA). 
 
Results 
 The ABI was less than 0.9 in 72 (8.4%) patients. The mean baPWV was 2059 ± 491 
cm/s. On plotting the values of the ABI and baPWV, there were linear associations between 
these values, separately for both a low ABI (<0.9) and high ABI (≥0.9) (Figure 2). Poor 
outcome 3 months after onset was noted in 254 (29.5%) patients. An ABI <0.9 and the 
baPWV were associated with poor outcome in the univariate analysis (p < 0.001 and p < 
0.001, respectively). And, a cutoff of baPWV for predicting poor outcome was 1870 cm/s. 
 The patients were categorized into four groups by combination of ABI (ABI <0.9 or 
≥0.9) and baPWV (baPWV >1870 cm/s or ≤1870 cm/s). We classified patients with ABI ≥0.9 
and baPWV ≤1870 cm/s as group 1 (n=316), ABI ≥0.9 and baPWV >1870 cm/s as group 2 
(n=473), ABI <0.9 and baPWV ≤1870 cm/s as group 3 (n=21), and ABI <0.9 and baPWV 
>1870 cm/s as group 4 (n=51). The baseline characteristics of the patients are presented in 
Table 1. Age, BMI, ischemic stroke subtype, NIHSS score on admission, smoking, 
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hypertension, diabetes mellitus, and usage of antithrombotic agent were significantly different 
among four groups. NIHSS score was higher in group 4 than group 1 (P =0.002). The 
proportions of poor outcome (3 months mRS, 2–6) were significantly higher in the group 3 
and 4 (p <0.001, Figure 3). With multivariate logistic regression models adjusted with these 
factors, group 2 showed slightly high odds ratio compared with group 1, although there was 
no statistical significance. Group 3 and 4 significantly associated with poor outcome (Table 
3). 
 
Discussion 
 In our study, among first-ever non-cardioembolic stroke patients, an ABI <0.9 and 
baPWV was associated with the outcome 3 months after stroke onset. The outcome 3 months 
after stroke onset was poorer in patients with an ABI <0.9 than in those with an ABI ≥0.9. 
Within the subjects with ABI ≥0.9, baPWV >1870 cm/s had some prognostic value of poor 
outcome in comparison with the subjects with baPWV≤1800 cm/s. 
 It has been reported that a low ABI of <0.9 has a prognostic value for mortality and 
the incidences of coronary artery disease and stroke in the general population18, 19). In our 
study, 68.1% of the patients with a low ABI showed poor outcome 3 months after the events. 
A low ABI showed high predictivity for poor outcome 3 months after the events. Kim et al. 
reported that, in acute first-ever stroke patients, an ABI <0.9 was a predictive factor for mRS 
0–2 3 month after stroke onset7). A previous study reported that the mortality rate of ischemic 
stroke patients increases when peripheral artery disease is also present20). Some studies 
showed an association between an ABI <0.9 and an increase in mortality or recurrence of 
stroke in acute stroke patients; therefore, poor outcome at 3 months may result from high 
mortality or recurrence of stroke18, 21-23). In our study, the mortality rate was 4.3% in the low 
ABI patients and was 1.6% in the high ABI patients. Additionally, the stroke severity at 
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admission was higher in the low ABI patients than in the high ABI patients. Therefore, it may 
have an influence on poor outcome. 
 Peripheral artery disease has been shown to be present in 10.1% of cerebrovascular 
disease patients24). In the present study, an ABI <0.9 was noted in 8.4% of patients. A recent 
study showed that 20.1% of patients with acute ischemic stroke or transient ischemic attack 
were diagnosed with peripheral artery disease on computed tomography angiography, and the 
proportion of patients with a low ABI was 12.2%25). The criterion of an ABI <0.9 may 
underestimate the presence of peripheral artery disease, although it is widely used as a 
surrogate marker for peripheral artery disease. In this study, we did not perform any 
additional evaluation for peripheral artery disease. Therefore, there may be a higher 
proportion of patients with peripheral artery disease than was detected with a low ABI. 
 The findings of our study suggest that a high baPWV is a weak predictive factor for 
poor outcome when the ABI is ≥0.9. Our scatter plot of the ABI and baPWV, and their 
regression lines suggested that the accuracy of the baPWV may diminish when the ABI is 
<0.9. Our results are supported by the findings of a previous study that reported associations 
of mortality with the ABI and baPWV in dialysis patients26). In this previous study, a high 
baPWV predicted mortality only in patients with an ABI ≥0.9. Kim et al. reported an 
association between the baPWV and the long-term outcome of acute first-ever stroke, without 
consideration of the ABI8). They showed that patients with the highest baPWV tertile had a 
significantly high OR of poor outcome in comparison to patients with the lowest tertile. The 
proportion of patients with an ABI <0.9 was slightly higher in this previous study (8.8%) than 
in our study (8.4%). Additionally, the proportion of patients with an ABI <0.9 was lower in 
their lowest baPWV tertile (<1755 cm/s, 6.3%) than in our lower baPWV (<1870 cm/s, 9.7%). 
Ishizuka K et al. also reported an association between baPWV and 3-month mRS in acute 
stroke patients without consideration of the ABI9). Their study population was relatively small 
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(n=327), and a proportion of mRS ≥3 was higher (32.1%) than our study (16.4%). It was not 
provided the proportion of low ABI or PAD in their subjects. Moreover, both of the previous 
reports included a stroke subtype of cardioembolic stroke. These differences might account 
for the inconsistent results between these previous studies and our study.  
 Our study indicates that the predictive power of the baPWV is weaker than that of the 
ABI for the outcome of non-cardioembolic stroke. There are several explanations for this 
result. First, the baPWV was under estimated when patients had peripheral artery disease, as 
mentioned above. Moreover, the baPWV reflects the arterial stiffness that increases because 
of atherosclerosis. On the other hand, the ABI reflects stenosis or obstruction of the artery that 
reflects a progressed stage of atherosclerosis. Therefore, the ABI may reflect severe 
atherosclerosis that has an impact on stroke outcome more directly than the baPWV. 
 
Limitations 
 There are several limitations in this study. First, this study was a single hospital 
retrospective study. This setting may have caused selection bias in our results. Second, there 
were significant differences in stroke severity at admission among the groups. Especially, 
patients with an ABI <0.9 had a high NIHSS score at admission. Although we included the 
NIHSS score for adjustment in the models of multivariate analysis, the difference may have 
influenced the prediction of stroke outcome with the ABI and baPWV. 
 
Conclusion 
 Our study suggests that the stroke outcome can be predicted with the ABI, and 
slightly with baPWV when ABI ≥0.9 in non-cardioembolic stroke patients. Further studies 
evaluating the ABI or baPWV for their association with stroke outcome should be designed 
considering their inter-relationship.  
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Table 1. Characteristics among the patients categorized with the ABI and baPWV  
ABI, ankle brachial index; baPWV, brachial-ankle pulse wave velocity; LAA, large artery 
atherosclerosis; SVO, small vessel occlusion; NIHSS, National Institutes of Health stroke 
scale; IQR, interquartile raange; 3M mRS, modified Rankin scale 3-month after onset  
 
 Group 1 
 
ABI≥0.9 
baPWV≤1870 
cm/s 
 
N=316 
Group 2 
 
ABI≥0.9 
baPWV>1870 
cm/s 
 
N=473 
Group 3 
 
ABI<0.9 
baPWV≤1870 
cm/s 
 
N=21 
Group 4 
 
ABI<0.9 
baPWV>1870 
cm/s 
 
N=51 
 
 
 
P value 
Age, years 63.2± 11.8 74.1± 9.1 72.5± 14.4 76.9± 8.7 <0.001 
Female, n (%) 101 (32.0) 160 (33.8) 9 (42.9) 15 (29.4) 0.679 
BMI 23.9± 3.6 23.2± 3.4 23.3± 2.8 23.0± 3.7 0.019 
Ischemic stroke 
 Subtype 
    <0.001 
LAA, n (%) 76 (24.1) 127 (26.9) 11 (52.3) 27 (53.0)  
SVO, n (%) 129 (40.8) 166 (35.1) 4 (19.1) 10 (19.6)  
Other, n (%) 24 (7.6) 19 (4.0) 2 (9.5) 2 (3.9)  
Undetermined, n (%) 87 (27.5) 161 (34.0) 4 (19.1) 12 (23.5)  
NIHSS score on 
 admission 
(median [IQR]) 
2 [1–3] 2 [1–4] 3 [1–4] 4 [2–5] 0.002 
Drinking, n (%) 143 (45.4) 190 (40.6) 6 (28.6) 20 (39.2) 0.310 
Smoking, n (%) 177 (56.0) 178 (38.4) 11 (52.4) 23 (45.1) <0.001 
Hypertension, n (%) 211 (69.6) 374 (81.1) 16 (76.2) 47 (92.2) <0.001 
Dyslipidemia, n (%) 189 (60.4) 272 (58.0) 12 (57.1) 28 (56.0) 0.889 
Diabetes 
 mellitus, n (%) 
99 (31.5) 176 (37.5) 11 (52.4) 27 (52.9) 0.008 
Antithrombotic 
 agent, n (%) 
23 (7.3) 60 (12.7) 5 (23.8) 13 (25.5) <0.001 
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Table 2. Odds ratio for poor outcome of groups categorized with ABI and baPWV 
Odds ratio (95% confidence intervals) was calculated with multivariate logistic regression 
analysis adjusted with age, body mass index, large artery atherosclerosis, National Institute of 
Health stroke scale on admission, smoking, diabetes mellitus, and antithrombotic agent, 
which associated with poor outcome.  
ABI, ankle brachial index; baPWV, brachial-ankle pulse wave velocity. 
 ABI≥0.9 ABI<0.9 
baPWV≤1870 
Group 1 
N=316 
1.0 (reference) 
Group 3 
N=21 
5.19 (1.85-15.14) 
baPWV>1870 
Group 2 
N=473 
1.46 (0.95-2.27) 
Group 4 
N=51 
3.37 (1.63-7.08) 
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Figure Legends 
Figure 1. Flow chart of inclusion and exclusion criteria 
 
Figure 2. Scatter plot of the ABI and baPWV, and their regression lines 
There are linear associations between these factors, separately for both a low ABI (<0.9) and 
a high ABI (≥0.9). 
ABI, ankle brachial index; baPWV, brachial-ankle pulse wave velocity 
 
Figure 3. Proportion of subjects who showed poor outcome (3M mRS 2-6) and mortality 
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